- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
5 result(s) found for: Lymphangioleiomyomatosis.
Displaying page 1 of 1.
| EudraCT Number: 2007-003745-32 | Sponsor Protocol Number: 7061 | Start Date*: 2008-12-12 | ||||||||||||||||
| Sponsor Name:University of Nottingham | ||||||||||||||||||
| Full Title: A randomised, double blind, placebo controlled trial of doxycycline in lymphangioleiomyomatosis. | ||||||||||||||||||
| Medical condition: Lymphangioleiomyomatosis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2015-004919-20 | Sponsor Protocol Number: StudioLAM | Start Date*: 2016-03-09 | |||||||||||
| Sponsor Name:MULTIMEDICA S.P.A. | |||||||||||||
| Full Title: A pilot study of nintedanib for lymphangioleiomyomatosis (LAM) | |||||||||||||
| Medical condition: Female subjects affected by Llymphangioleiomyomatosis (LAM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000702-29 | Sponsor Protocol Number: LORALAM-2020 | Start Date*: 2021-06-07 | |||||||||||
| Sponsor Name:IDIBELL (Institut d’Investigació Biomédica de Bellvitge) | |||||||||||||
| Full Title: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM). | |||||||||||||
| Medical condition: EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019825-32 | Sponsor Protocol Number: CRAD001X2201 | Start Date*: 2010-07-28 | |||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||
| Full Title: An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis. | |||||||||||||
| Medical condition: Lymphangioleiomyomatosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-002113-48 | Sponsor Protocol Number: CRAD001M2302 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A randomized double-blind, placebo-controlled study of RAD001 in the treatment of Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | |||||||||||||
| Medical condition: Angiomyolipoma in patients with either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.